Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study
Conclusion Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 on Day 1 q3wk has shown noteworthy activity in relapsed SCLC and a manageable safety profile. The combination is being evaluated as second-line therapy for SCLC in an ongoing, randomized phase III trial.Clinical trial registrationwww.ClinicalTrials.gov code: NCT01970540. Date of registration: 22 October, 2013.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Alopecia | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Drugs & Pharmacology | Hematology | Investigational New Drugs | Lung Cancer | Small Cell Lung Cancer | Study | Toxicology